Sanofi Set for Dupixent’s Pediatric Eczema Filing in Japan after Positive Data

Sanofi said on June 14 that its atopic dermatitis (AD) treatment Dupixent (dupilumab) hit the primary endpoint in a Japanese PIII study conducted in children aged six months to 18 years, setting the stage for the company to seek a...read more